Bisphosphonate Drug Holiday and Fracture Risk: Reviewing the Evidence

Purpose of review This paper reviews evidence in support of or counter to the use of bisphosphonate (BP) drug holiday to minimize the occurrence of rare adverse events such as atypical femoral fracture, while maintaining the osteoporosis-related fracture prevention benefit conferred by the medicatio...

Full description

Saved in:
Bibliographic Details
Published in:Current treatment options in rheumatology 2022-07, Vol.8 (3), p.37-55
Main Authors: Adams, Annette L., Ryan, Denison S., Lawless, Anna, Fischer, Heidi
Format: Article
Language:English
Subjects:
Medicine
Medicine & Public Health
Osteoporosis (K Saag
Rheumatology
Section Editor
Topical Collection on Osteoporosis
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose of review This paper reviews evidence in support of or counter to the use of bisphosphonate (BP) drug holiday to minimize the occurrence of rare adverse events such as atypical femoral fracture, while maintaining the osteoporosis-related fracture prevention benefit conferred by the medication. Recent findings Fracture prevention benefit achieved with 3–5 years of BP treatment appears to be maintained during holiday for women at low to moderate risk of fracture. Women with bone mineral density T-score 
ISSN:2198-6002
2198-6002
DOI:10.1007/s40674-022-00191-8